Incyte's revenues continues to grow, with full-year 2024 revenues reaching $4.2 billion, driven by JAKAFI and OPZELURA. Click ...

BEDFORD, Mass. - Stoke Therapeutics, Inc. (NASDAQ: STOK) shares dropped 4.1% after the biotechnology company announced its CEO Edward M. Kaye will step down, overshadowing better-than-expected fourth ...

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against other best ...

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Exelixis, Inc.

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...

It’s a tough job analysing share prices and company performances in the middle of a sharp share market downturn, but ...

Insiders are still scooping up shares of stocks, including huge buys at two energy companies, an apparel retailer, and a ...

With a promising outlook for PTC India and Piramal Pharma, Bajaj Broking identifies key stock picks poised for over 15% ...

Officers, beneficial owners, and other insiders have shelled out more than $10 million on each of these four biotech stocks ...

Abecma made $406 million in 2024, of which BMS paid $43 million to 2seventy bio as part of their profit-sharing agreement.

Brokerages have revealed a favourable outlook for the stock with the acquisition expected to be completed by the second half of 2025.